Program and patient characteristics for the United States Expanded Access Program to COVID-19 convalescent plasma

BACKGROUND: The United States (US) Expanded Access Program (EAP) to COVID-19 convalescent plasma was initiated in response to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease-2019 (COVID-19). While randomized clinical trials...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:medRxiv
Hoofdauteurs: Senefeld, Jonathon W., Johnson, Patrick W., Kunze, Katie L., van Helmond, Noud, Klassen, Stephen A., Wiggins, Chad C., Bruno, Katelyn A., Golafshar, Michael A., Petersen, Molly M., Buras, Matthew R., Klompas, Allan M., Sexton, Matthew A., Soto, Juan C. Diaz, Baker, Sarah E., Shepherd, John R.A., Verdun, Nicole C., Marks, Peter, van Buskirk, Camille M., Winters, Jeffrey L., Stubbs, James R., Rea, Robert F., Herasevich, Vitaly, Whelan, Emily R., Clayburn, Andrew J., Larson, Kathryn F., Ripoll, Juan G., Andersen, Kylie J., Vogt, Matthew N.P., Dennis, Joshua J., Regimbal, Riley J., Bauer, Philippe R., Blair, Janis E., Wright, Katherine, Greenshields, Joel T., Paneth, Nigel S., Fairweather, DeLisa, Wright, R. Scott, Casadevall, Arturo, Carter, Rickey E., Joyner, Michael J.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Cold Spring Harbor Laboratory 2021
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8043472/
https://ncbi.nlm.nih.gov/pubmed/33851175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.04.08.21255115
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items